pyrazines has been researched along with alpha-synuclein in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bonhaus, D; Khan, A; Koike, MA; Masliah, E; Price, DL; Rockenstein, E; Wrasidlo, W | 1 |
| Guo, B; Lee, SM; Li, C; Li, H; Lu, J; Lu, Y; Shao, M; Wang, Y; Yang, X; Zhang, Z; Zhong, H; Zhou, H; Zhu, Q | 1 |
2 other study(ies) available for pyrazines and alpha-synuclein
| Article | Year |
|---|---|
The small molecule alpha-synuclein misfolding inhibitor, NPT200-11, produces multiple benefits in an animal model of Parkinson's disease.
Topics: alpha-Synuclein; Animals; Cerebral Cortex; Disease Models, Animal; Gene Expression Regulation; Humans; Inflammation; Lewy Body Disease; Mice; Mice, Transgenic; Multiple System Atrophy; Neurons; Parkinson Disease; Piperidines; Protein Aggregation, Pathological; Protein Folding; Pyrazines; Pyrimidines; Retina | 2018 |
Tetramethylpyrazine Analogue T-006 Promotes the Clearance of Alpha-synuclein by Enhancing Proteasome Activity in Parkinson's Disease Models.
Topics: alpha-Synuclein; Animals; Dose-Response Relationship, Drug; Humans; Hydrazones; Mice; Mice, Transgenic; Parkinson Disease; PC12 Cells; Proteasome Endopeptidase Complex; Pyrazines; Rats; Vasodilator Agents | 2019 |